Loading
Eagle Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Meyers Pete A., was filed 16 Aug 2017.
Insider Decl.
329
Thresholds
n/a
Buy Volume
€12M
15 ops. · all time
Sell Volume
€129M
165 ops. · all time
Since the insiders bought
- +39.5%Entry US$56.02 · Close at T+365 US$78.14
- -16.9%Entry US$77.55 · Close at T+365 US$64.46
- +51.4%Entry US$53.68 · Close at T+365 US$81.27
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 524 of 26,290 companies
84.1
score / 100
Value100
Quality69
FCF yld·
Earn yld·
EV/EBITDA0.9x
ROE4.9%
Gross mgn70%
Net mgn11%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2022FY ended December 2022 · cache
US$0.25
Analyst consensus
Income statement
RevenueUS$316.6M
Gross profitUS$221.7M70% margin
EBITDAUS$77.5M24% margin
Net incomeUS$35.6M4.6% margin
Valuation
PER (trailing)0.2x
P/Book0.0x
Beta0.87
Balance sheet & cash
Market capUS$3.3M
Total debtUS$64M
Free Cash FlowUS$50.5M
Debt / Equity29%
Profitability & ownership
ROE4.9%
ROA6.6%
% institutions43.3%
Last declaration on 1 March 2024
Declarations329 total
2,119 shares@ US$6.271.0% of flowCommon StockSEC:0000950170-24-023945:0
1,589 shares@ US$6.44Common StockSEC:0001415889-24-006003:1
3,154 shares@ US$6.44Common StockSEC:0000950170-24-023198:1
12,950 sharesCommon StockSEC:0000950170-24-023198:0
3,800 shares0Common StockSEC:0001415889-24-006003:0
934 shares@ US$5.852.2% of flowCommon StockSEC:0001415889-24-002831:0
4,322 shares@ US$5.131.7% of flowCommon StockSEC:0000950170-24-003397:0
735 shares@ US$5.131.5% of flowCommon StockSEC:0001209191-24-001256:0
452 shares@ US$4.760.9% of flowCommon StockSEC:0001209191-23-059344:0
10,694 shares@ US$13.87Common StockSEC:0001209191-23-054333:1
10,925 shares@ US$13.8212.1% of flowCommon StockSEC:0001209191-23-054333:0
9,360 shares@ US$4.94100.0% of flowCommon StockSEC:0001209191-23-053969:0
10,024 shares@ US$14.41Common StockSEC:0001209191-23-052030:1
710 shares@ US$15.11Common StockSEC:0001209191-23-052030:2
9,511 shares@ US$15.2311.7% of flowCommon StockSEC:0001209191-23-052030:0
15,000 shares@ US$19.9823.4% of flowCommon StockSEC:0001209191-23-030725:0
200 shares@ US$21.520.0% of flowCommon StockSEC:0001209191-23-029625:4
3,131 shares@ US$19.69Common StockSEC:0001209191-23-029625:1
11,869 shares@ US$20.42Common StockSEC:0001209191-23-029625:2
14,800 shares@ US$21.06Common StockSEC:0001209191-23-029625:3
15,000 shares@ US$20.7124.2% of flowCommon StockSEC:0001209191-23-029625:0
70,900 shares0Common StockSEC:0001209191-23-014646:1
18,500 shares0Common StockSEC:0001209191-23-014650:1
718 shares@ US$28.008.2% of flowCommon StockSEC:0001209191-23-014650:0
3,113 shares@ US$28.007.0% of flowCommon StockSEC:0001209191-23-014646:0
25 of 329 declarations
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a US healthcare and pharma company listed on Nasdaq, has 259 filings published from January 5, 2016 to March 1, 2024, from 17 filers, and none in the last twelve months. It is a record of sales: 137 sales against 12 purchases, or 8% purchases among open-market trades, though only 41 sales and 7 purchases carry an amount.
The three largest sales are all by Scott Tarriff, filed as President and CEO: EUR 929,257 in January 2016, then EUR 332,919 and EUR 327,347 on February 1, 2016. The sales with an amount reach EUR 3.36 million in all. The purchases with an amount total EUR 47,911; the largest, EUR 47,530, is by director Steven B. Ratoff, and the others are minimal sums, such as the EUR 74 of David Pernock, Pres. & Chief Comm. Officer, in March and May 2017.
Read moreShow less
ProQuest Investments IV, L.P., a holder of more than 10% of the securities, is the top filer with 75 filings, 65 of them sales; Scott Tarriff files 50, 31 of them sales. There are 67 grants and 36 option exercises. Activity peaks in 2016 (79 filings) and 2017 (61), then falls to 9 in 2018 and 8 in 2024. Filings are published a median of 2 days after the trade.
